Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Across all cancers: a drug is placed once, at the highest stage it reaches anywhere. Representative drugs are those with the most active trials at that stage.
86 drugs · 711 active trials
22 drugs · 920 active trials
348 drugs · 19,214 active trials
Outside the funnel: Withdrawn 25. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 7 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Nelarabine | Approved | Phase 3 | 6 | 3 | 6 | 30 | 4 | CA, EU, US | Oct 28, 2005 | 1997-06 |
| Dordaviprone | Approved | Phase 3 | 6 | 6 | 2 | 26 | 1 | US | Aug 6, 2025 | 2014-01 |
| Brexucabtagene Autoleucel | Approved | Phase 2 | 6 | 4 | 0 | 12 | 3 | CA, EU | Dec 14, 2020 | Nov 9, 2015 |
| Repotrectinib | Approved | Phase 3 | 6 | 5 | 1 | 12 | 6 | CA, EU, US | Nov 15, 2023 | Mar 7, 2017 |
| Alemtuzumab | Approved | Phase 3 | 5 | 0 | 4 | 139 | 5 | EU, US | May 7, 2001 | 2000-01 |
| Romidepsin | Approved | Phase 3 | 5 | 3 | 4 | 83 | 5 | CA, US | Nov 5, 2009 | 1997-08 |
| Flutamide | Approved | Phase 4 | 5 | 1 | 25 | 52 | 12 | CA, US | Oct 8, 1998 | 1994-10 |
| Aminolevulinic Acid | Approved | Phase 4 | 5 | 4 | 4 | 40 | 9 | CA, US | Dec 3, 1999 | 1993-11 |
| Tivozanib | Approved | Phase 3 | 5 | 4 | 5 | 31 | 2 | EU, US | Aug 24, 2017 | 2007-10 |
| Treosulfan | Approved | Phase 3 | 5 | 5 | 4 | 28 | 6 | CA, EU, US | Jun 20, 2019 | 2001-11 |
| 5-Aminolevulinic Acid | Approved | Phase 4 | 5 | 4 | 4 | 25 | 2 | EU | Sep 7, 2007 | 1999-10 |
| Verteporfin | Approved | Phase 2 | 5 | 4 | 0 | 11 | 3 | US | Apr 12, 2000 | 1994-05 |
| Nadofaragene Firadenovec | Approved | Phase 4 | 5 | 4 | 5 | 9 | 2 | CA, EU | May 28, 2026 | 2012-09 |
| Dinutuximab Beta | Approved | Phase 3 | 5 | 3 | 1 | 7 | 1 | EU | May 8, 2017 | 2013-07 |
| Ciltacabtagene Autoleucel | Approved | Phase 2 | 5 | 3 | 0 | 6 | 2 | CA, EU | May 25, 2022 | Jun 29, 2018 |
| Lapatinib | Approved | Phase 4 | 4 | 1 | 33 | 217 | 7 | CA, EU, US | Mar 13, 2007 | 2002-09 |
| Ofatumumab | Approved | Phase 4 | 4 | 3 | 12 | 81 | 8 | CA, EU, US | Oct 26, 2009 | 2004-09 |
| Tisotumab Vedotin | Approved | Phase 4 | 4 | 1 | 2 | 13 | 3 | EU, US | Sep 20, 2021 | Nov 30, 2013 |
| Sugemalimab | Approved | Phase 3 | 4 | 3 | 3 | 11 | 1 | EU | Jul 24, 2024 | Oct 19, 2017 |
| Ripretinib | Approved | Phase 3 | 4 | 2 | 3 | 10 | 3 | CA, EU, US | May 15, 2020 | 2015-11 |
| Taletrectinib | Approved | Phase 3 | 4 | 2 | 2 | 7 | 1 | US | Jun 11, 2025 | Feb 10, 2016 |
| Histrelin | Approved | Phase 3 | 4 | 2 | 4 | 6 | 2 | CA, US | May 3, 2007 | 2000-04 |
| Nogapendekin Alfa Inbakicept | Approved | Phase 3 | 4 | 2 | 1 | 6 | 2 | EU, US | Apr 22, 2024 | Apr 13, 2026 |
| Obecabtagene Autoleucel | Approved | Phase 2 | 4 | 3 | 0 | 4 | 1 | EU | Jul 17, 2025 | Jun 3, 2020 |
| Pimicotinib | Approved | Phase 3 | 4 | 2 | 1 | 4 | 1 | CA | Aug 12, 2026 | Apr 27, 2023 |
| Sorafenib Tosylate | Approved | Phase 3 | 3 | 0 | 11 | 134 | 9 | US | Dec 1, 2005 | 2004-08 |
| Vandetanib | Approved | Phase 4 | 3 | 1 | 9 | 97 | 6 | CA, EU, US | Apr 6, 2011 | 2002-05 |
| Sonidegib | Approved | Phase 4 | 3 | 1 | 0 | 36 | 4 | CA, EU, US | Jul 24, 2015 | 2009-03 |
| Pasireotide | Approved | Phase 4 | 3 | 2 | 4 | 28 | 4 | US | Dec 14, 2012 | 2004-01 |
| Pexidartinib | Approved | Phase 4 | 3 | 2 | 2 | 25 | 3 | US | Aug 2, 2019 | Oct 1, 2009 |
| Azathioprine | Approved | Phase 4 | 3 | 1 | 2 | 11 | 2 | US | Mar 20, 1968 | Jan 1, 2007 |
| Idecabtagene Vicleucel | Approved | Phase 3 | 3 | 0 | 2 | 10 | 2 | CA, EU | Aug 18, 2021 | Dec 22, 2015 |
| Nilutamide | Approved | Phase 3 | 3 | 1 | 5 | 10 | 7 | CA, US | Jul 15, 2016 | Feb 8, 1995 |
| Momelotinib | Approved | Phase 2 | 3 | 3 | 0 | 7 | 5 | CA, EU, US | Sep 15, 2023 | Feb 19, 2014 |
| Osimertinib Mesylate | Approved | Phase 3 | 3 | 2 | 1 | 5 | 13 | US | Nov 13, 2015 | Aug 6, 2021 |
| Telmisartan | Approved | Phase 2 | 3 | 2 | 0 | 4 | 1 | US | Jan 8, 2014 | Apr 9, 2020 |
| Vimseltinib | Approved | Phase 3 | 3 | 0 | 1 | 4 | 3 | EU, US | Feb 14, 2025 | Feb 16, 2017 |
| Panobinostat | Approved | Phase 4 | 2 | 1 | 3 | 116 | 1 | EU | Aug 28, 2015 | Mar 1, 2003 |
| Aflibercept | Approved | Phase 3 | 2 | 1 | 11 | 74 | 16 | CA, EU, US | Nov 18, 2011 | 2001-11 |
| Nintedanib | Approved | Phase 3 | 2 | 0 | 5 | 71 | 17 | CA, EU, US | Oct 15, 2014 | 2002-11 |
| Raltitrexed | Approved | Phase 4 | 2 | 1 | 3 | 33 | 1 | CA | Nov 18, 1996 | 1993-09 |
| Vinflunine | Approved | Phase 3 | 2 | 1 | 12 | 26 | 1 | EU | Sep 21, 2009 | 2005-01 |
| Ibuprofen | Approved | Phase 4 | 2 | 1 | 4 | 20 | 14 | US | Jun 16, 1995 | 2001-02 |
| Mechlorethamine | Approved | Phase 3 | 2 | 0 | 4 | 14 | 2 | CA, US | Aug 23, 2013 | 1989-02 |
| Tofacitinib | Approved | Phase 4 | 2 | 2 | 8 | 14 | 22 | US | Nov 6, 2012 | 2009-10 |
| Fedratinib | Approved | Phase 3 | 2 | 1 | 3 | 12 | 3 | CA, EU, US | Aug 16, 2019 | 2011-08 |
| Mitotane | Approved | Phase 3 | 2 | 2 | 4 | 8 | 3 | CA, EU, US | Jul 8, 1970 | 2004-06 |
| Sevabertinib | Approved | Phase 3 | 2 | 2 | 1 | 7 | 3 | CA, US | Nov 19, 2025 | Jan 25, 2024 |
| Buserelin | Approved | Phase 3 | 2 | 0 | 5 | 6 | 7 | CA | Dec 30, 1996 | Feb 8, 1995 |
| Roflumilast | Approved | Phase 1 | 2 | 2 | 0 | 4 | 10 | US | Feb 28, 2011 | 2013-07 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.